INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...
We are excited to have completed administering first doses to all patients enrolled in our phase 2 Alzheimer’s trial,” stated RJ Tesi PhD, the CEO of INmune Bio. “A global trial of this size is a ...
As global AI spending is projected to add USD 15.7 trillion to the world economy by 2030 according to PwC’s Global Artificial Intelligence Study, the demand for skilled professionals to harness AI ...